Spin-off dell'Universita' di Osaka: piattaforma POCT compatta e ad alta sensibilita' basata sulla tecnologia immunologica GLEIA.
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Funding round Immunosens raised an unquantified round (equity and debt) with Shimadzu Future Innovation Fund, Kansai Mirai Venture Fund, SMBC VC and bank loans. | — |